-
2023: The Year in Cancer News
The Cancer Today editors share the most impactful reporting and essays of 2023.
by Cancer Today staff
-
Emerging Treatments for Brain Metastases in Breast Cancer
SABCS panel describes advances and pivotal questions in managing patients whose breast cancer has metastasized to their brain.
by Marci A. Landsmann
-
Cancer Today Editors’ Picks: 2023
The editors of Cancer Today share the stories that most resonated with readers in 2023.
-
Patient Advocates as Research Partners
Speakers at SABCS discuss how people who have lived with breast cancer can be valuable partners in research.
by Eric Fitzsimmons
-
Understanding Side Effects and the Patient Experience
Researchers focus on assessing quality of life and toxicity risks in people with breast cancer.
by Thomas Celona
-
Addressing Social Determinants of Health
Speakers at SABCS discuss measuring and meeting social factors that affect the health and outcomes of breast cancer patients.
by Kevin McLaughlin
-
Exercise Benefits in Metastatic Breast Cancer
Study finds supervised physical activity can help improve quality of life and reduce fatigue among people with metastatic breast cancer.
by Thomas Celona
-
Finding Answers in Prostate Cancer
PSMA PET imaging is helping clinicians more accurately stage prostate cancer and provide precision treatment.
by Sandra Gordon
-
Is Chemo-free Treatment Coming for HER2-positive Breast Cancer?
Evidence grows that some people with HER2-positive breast cancer may do well on HER2-targeted therapy alone.
by Myles Starr
-
Germline Genetic Testing Lags Behind Guidelines
Low rates of germline genetic testing in cancer patients means information that could affect treatment isn’t available.
by Jon Kelvey
Cancer Talk
Immunotherapy Improves Survival in Bladder Cancer
New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
2024: The Year in Cancer NewsThe Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff